AnaptysBio Inc (ANAB) 股票價格預測

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2017-01-26. The firm is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. The company has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.